CLINICAL TRIALS OF INACTIVATED CULTURE VACCINE AGAINST CAMELPOX ON NATURALLY SUSCEPTIBLE ANIMALS

Abstract

In the development of inactivated culture vaccine against camelpox, the deposited strain of camelpox virus M-0001, isolated in one of the farms of Mangistau region Beineuovskiy district in 2020, was used. For inactivation 0.05 % of final concentration of inactivant ß-propiolactone was used. To stimulate the immune response was used adjuvant Montanidae Gel01 in 1% concentration. The true state of immunity of the livestock during immunoprophylaxis will be determined by the results of routine immunologic (serologic) monitoring and elimination of the emerging focus of infection. For the purpose of approbation of the culture inactivated anti-vax vaccine from the strain "M- 0001" against camel pox in production conditions, the vivarium of SPE "Antigen" LLP was used as a base. Immunogenicity of the vaccine was tested on 3 camels, which were injected with the vaccine subcutaneously in a dose of 3.0 cm3 in the groin area. In vaccinated animals with inactivated culture vaccine against camelpox from the strain "M-0001" on the 0 day the antibody titer against smallpox showed negative results, on the 7 day it was 1:2 - 1:4, on the 14 day it was 1:4-1:8, on the 21 day the antibody titer was 1:8.